AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: arnie h who wrote (1379)	5/20/1998 1:09:00 AM
From: D.Right	Read Replies (2) of 2173

Dear Arnie: Thanks for the post. I do think the weakening trend was due to the increased dose of insulin by many patients. A while back, on the Yahoo AMLN board, a participant of the trial for type I posted that he experienced about 2% drop of HbA1c. If it is the case, then the drug group will have less need to increase insulin. Because the increase of insulin by patients is always a gradual process, in a year the placebo group will have more insulin increased than half year. The question is whether the measure AMLN is taking now is effective or not in controlling the insulin change. As for comparing to antibody for cancer, it is quite different. The antibody was not made for the cancer fighting purpose naturally. On the other hand, amylin is secreted after meal together with insulin. It sure looks like a hormone for metabolism control. The concept of natural hormone replacement therapy is the main reason I believe that amylin will work. So, a mechanism of tolerance by the body over time is very unlikely. I will try to go to the annual meeting tomorrow, I am about 2 hours driving away from the co. If I go, I will post my thought later. D.Right

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next